See also this year's filing and all EDGAR filings for this company.
PDF Report 0001638287_2022_NeuroBo_Pharmaceuticals_Inc.pdf
Logs
| warning | Missing logo | subcommand.report | {} |
| info | Failed to set obs_EconomicCapitalRatio | industry.us_generic | {'reason': "KeyError('0001638287')"} |
| info | Ambiguous roles for statement | input.sec.calculation_linkbase.expand_agg | {'statement': 'operations', 'valid_roles': {'00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss': 9, '00205 - Statement - Condensed Statements of Comprehensive Loss (Calc 2)': 2}} |
| info | Added remainder_ComprehensiveNetIncome directly from 10K | industry.us_generic | {} |
Graph
Absolute values for 0001638287, NeuroBo Pharmaceuticals Inc.
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 16,584,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 110,000 |
| 3 | remainder_Assets | 105,000 |
| 4 | LiabilitiesCurrent | 2,157,000 |
| 5 | LiabilitiesNoncurrent | 45,000 |
| 6 | remainder_Liabilities | 0 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 8,752,000 |
| 9 | ResearchAndDevelopmentExpense | 6,546,000 |
| 10 | remainder_Expenses | 0 |
| 11 | remainder_Revenues | 0 |
| 12 | remainder_NetIncome | 14,000 |
| 13 | remainder_ComprehensiveNetIncome | -10,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 16,799,000 |
| 1 | Liabilities | 2,202,000 |
| 2 | Expenses | 15,298,000 |
| 3 | Revenues | 0 |
| 4 | StockholdersEquity | 14,597,000 |
| 5 | NetIncome | -15,284,000 |
| 6 | ComprehensiveNetIncome | -15,289,000 |
| 7 | BaseVar | 17,161,500 |
| 8 | EconomicCapitalRatio | 1.03 |
Edgar->Model Mapping
Feature Distribution
Change over Time
